Skip to content
Search

Latest Stories

Alliance Pharma founder donates £5m to create University of Sunderland's new drug research centre

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre.

The donation – the biggest in the university’s history – will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide.


The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding.

He and Sam were on Thursday (April 20) joined by specially invited guests from across the region’s health, education, and business communities, to launch the Institute housed in the University’s Sciences Complex.

2023pr047pic4 John Dawson and his wife Sam outside the John Dawson Drug Discovery and Development Research Institute at the University of Sunderland’s City Campus. Picture: DAVID WOOD

Unveiling a plaque inside the building, John said: “It’s an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today.

“It’s been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago.

“I was immediately impressed at what has been achieved in that intervening half-century and I’ve been delighted to assist the University continue its development, particularly in the health arena.

“I hope the launch of this institute will mark the next phase in the University’s evolution and I’m very much looking forward to working with the team as they bring their projects to fruition.”

The new institute will play a key role in turning laboratory research and innovation into life-changing therapies for clinical practice, working closely with the NHS and the pharmaceutical industry.

It will also bring together expertise in clinical, laboratory and data science to address issues of local, national and international importance and focus on on areas including the discovery of new medicines for the treatment of rare inherited metabolic diseases -- developing targeted delivery methods and technologies to improve pharmaceutical manufacturing processes as well as the development and application of machine learning tools for early disease detection.

2023pr047pic3 John Dawson and his wife Sam pictured with the university's vice chancellor and chief executive Sir David Bell (L). Picture: DAVID WOOD

Sir David Bell, Newcastle University’s vice-chancellor and chief executive, said: “I am enormously grateful to John and Sam Dawson for their immense generosity in supporting this new Research Institute in the crucially important fields of drug discovery and development.

"The fact that John is ‘one of us’ is an added bonus as his life and career demonstrate the good that our graduates do in so many different walks of life.”

After graduating from Sunderland Polytechnic in 1970, Newcastle-born John went on to build a successful career in the pharmaceutical industry. He founded the prescription medicines and consumer healthcare company, Alliance Pharma, in 1996.

Commenced trading in 1998 with just two full-time employees in the UK, the company expanded over the next 20 years. John turned it into an international pharmaceutical powerhouse with sales now exceeding £170m, operating out of nine offices in eight countries with more than 280 employees.

He stepped down from Alliance Pharma in 2019.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less